Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||CE7R CAR T cells|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CE7R CAR T cells||CD171 CAR+ T Cells|CD171-specific CAR-CD28 zeta-4-1-BB-EGFRt-expressing T cells||CE7R CAR T cells are autologous T-cells that are engineered to express a CD171-targeted chimeric antigen receptor that contains CD28, CD3zeta, and 4-1-BB signaling domains as well as truncated EGFR, which potentially increases cytoxicity in CD171-expressing tumors (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02311621||Phase I||CE7R CAR T cells||Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01||Active, not recruiting||USA||0|